Alert icon
We're changing our privacy policy. This stuff matters.  Learn more  Dismiss

Mayo Clinic Collaborative Research Focuses on Depression Treatments

Loading...

Sign in or sign up now!
1,619
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Feb 18, 2009

Researchers at Mayo Clinics campus in Jacksonville and Virginia Tech in Blacksburg, Va., through their technology commercialization efforts, have licensed compounds to Astra Zeneca for potential new drug therapies to treat depression. The collaboration advances both the development of novel compounds and supports ongoing research by Mayo and Virginia Tech in the area of triple reuptake inhibitors.
According to Elliott Richelson, M.D., Mayo Clinic, this is important because triple reuptake inhibitors block reuptake of the neurotransmitters serotonin, norepinephrine, and dopamine. Certain antidepressants currently available for patients suffering from depression, work by inhibiting or blocking serotonin reuptake. Others block both serotonin and norepinephrine reuptake. A key element in the way nerve cells work is when a neurotransmitter is released to relay its message, it returns to the nerve ending from which it was released. The mechanism of taking the neurotransmitter back into the nerve ending is called reuptake. In depression there are fewer neurotransmitters being released in the brain. By blocking the reuptake of all three neurotransmitters more neurotransmitters can be sent to the nerve cells. Mayos collaboration focuses on a new class of antidepressants that block the reuptake of all three neurotransmitters.

  • likes, 0 dislikes

Link to this comment:

Share to:

Uploader Comments (mayoclinic)

  • what is the new compund called, or is it not named yet?

  • @Automobile577

    It only has a laboratory name: PRC200. Elliott Richelson, MD

  • @mayoclinic Is this going through Clinical Trials yet? I feel I have treatment resistent depression. Can you help? Thank you.

  • @coolshit28

    Our compounds are still years away from clinical testing. However, there are major pharmaceutical companies working on new antidepressants of this class. These compounds are already in clinical trials.

see all

All Comments (5)

Sign In or Sign Up now to post a comment!
  • good luck !!!

Loading...

0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more